Abstract
Objective: The most effective available therapies for the anti-inflammatory treatment of juvenile idiopathic arthritis (JIA), such as the anti-tumor necrosis factor-α (TNF) agent etanercept (ENBREL, Wyeth Pharma), are targeting phagocytes. Although advice for the initiation of this therapy is given, the appropriate duration of treatment is yet unknown. Physicians individually decide when it seems safe to withdraw etanercept. The pro-inflammatory protein S100A12 (EN-RAGE), a ligand for the receptor RAGE found on endothelium and various inflammatory cells, is secreted by activated neutrophils. We analyzed serum levels of S100A12 to monitor neutrophil activation during anti-TNF therapy in JIA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
